Differences in the repertoire, regulation and function of Toll-like Receptors and inflammasome-forming Nod-like Receptors between human and mouse

Current Opinion in Microbiology

Volumn 16, Issue 3, 2013, Pages 303-310

  Ariffin, Juliana K ^a   Sweet, Matthew J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INFLAMMASOME; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 12; TOLL LIKE RECEPTOR 13; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VIRUS DNA;

ASPERGILLUS FUMIGATUS; FRANCISELLA TULARENSIS; HUMAN; HUMAN GENOME; INNATE IMMUNITY; NONHUMAN; PROTEIN FUNCTION; REVIEW; TOXOPLASMA GONDII; UROPATHOGENIC ESCHERICHIA COLI;

ASTEROIDEA; MUS;

EID: 84881550719     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2013.03.002     Document Type: Review

References (57)

1. Dinarello C.A. Anti-inflammatory agents: present and future. Cell 2010, 140:935-950.
2. Benton M.J., Donoghue P.C. Paleontological evidence to date the tree of life. Mol Biol Evol 2007, 24:26-53.
3. Mestas J., Hughes C.C.W. Of mice and not men: differences between mouse and human immunology. J Immunol 2004, 172:2731-2738.
4. Gharib W.H., Robinson-Rechavi M. When orthologs diverge between human and mouse. Brief Bioinform 2011, 12:436-441.
5. Messier-Solek C., Buckley K.M., Rast J.P. Highly diversified innate receptor systems and new forms of animal immunity. Semin Immunol 2010, 22:39-47.
6. Kumagai Y., Akira S. Identification and functions of pattern-recognition receptors. J Allergy Clin Immunol 2010, 125:985-992.
7. Schattgen S.A., Fitzgerald K.A. The PYHIN protein family as mediators of host defenses. Immunol Rev 2011, 243:109-118.
8. Zhang Q., Zmasek C.M., Godzik A. Domain architecture evolution of pattern-recognition receptors. Immunogenetics 2010, 62:263-272.
9. Roach J.C., Glusman G., Rowen L., Kaur A., Purcell M.K., Smith K.D., Hood L.E., Aderem A. The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci USA 2005, 102:9577-9582.
10. Guan Y., Ranoa D.R., Jiang S., Mutha S.K., Li X., Baudry J., Tapping R.I. Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. J Immunol 2010, 184:5094-5103.
11. Yarovinsky F., Zhang D., Andersen J.F., Bannenberg G.L., Serhan C.N., Hayden M.S., Hieny S., Sutterwala F.S., Flavell R.A., Ghosh S., et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 2005, 308:1626-1629.
12. Zhang D., Zhang G., Hayden M.S., Greenblatt M.B., Bussey C., Flavell R.A., Ghosh S. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004, 303:1522-1526.
13. Shi Z., Cai Z., Sanchez A., Zhang T., Wen S., Wang J., Yang J., Fu S., Zhang D. A novel Toll-like receptor that recognizes vesicular stomatitis virus. J Biol Chem 2011, 286:4517-4524.
14. Oldenburg M., Kruger A., Ferstl R., Kaufmann A., Nees G., Sigmund A., Bathke B., Lauterbach H., Suter M., Dreher S., et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science 2012, 337:1111-1115.
15. Hidmark A., von Saint Paul A., Dalpke A.H. Cutting edge: TLR13 is a receptor for bacterial RNA. J Immunol 2012, 189:2717-2721.
16. Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Wagner H., Lipford G., Bauer S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002, 3:499.
17. Martinez J., Huang X., Yang Y. Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA. Proc Natl Acad Sci USA 2010, 107:6442-6447.
18. Gorden K.K., Qiu X.X., Binsfeld C.C., Vasilakos J.P., Alkan S.S. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J Immunol 2006, 177:6584-6587.
19. Rubino I., Coste A., Le Roy D., Roger T., Jaton K., Boeckh M., Monod M., Latge J.P., Calandra T., Bochud P.Y. Species-specific recognition of Aspergillus fumigatus by Toll-like receptor 1 and Toll-like receptor 6. J Infect Dis 2012, 205:944-954.
20. Rossol M., Heine H., Meusch U., Quandt D., Klein C., Sweet M.J., Hauschildt S. LPS-induced cytokine production in human monocytes and macrophages. Crit Rev Immunol 2011, 31:379-446.
21. Rehli M. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 2002, 23:375-378.
22. Schroder K., Irvine K.M., Taylor M.S., Bokil N.J., Le Cao K.A., Masterman K.A., Labzin L.I., Semple C.A., Kapetanovic R., Fairbairn L., et al. Conservation and divergence in Toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages. Proc Natl Acad Sci USA 2012, 109:E944-E953.
23. Heinz S., Haehnel V., Karaghiosoff M., Schwarzfischer L., Muller M., Krause S.W., Rehli M. Species-specific regulation of Toll-like receptor 3 genes in men and mice. J Biol Chem 2003, 278:21502-21509.
24. Netea M.G., Wijmenga C., O'Neill L.A. Genetic variation in Toll-like receptors and disease susceptibility. Nat Immunol 2012, 13:535-542.
25. Herman M., Ciancanelli M., Ou Y.H., Lorenzo L., Klaudel-Dreszler M., Pauwels E., Sancho-Shimizu V., Perez de Diego R., Abhyankar A., Israelsson E., et al. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J Exp Med 2012, 209:1567-1582.
26. Guo Y., Audry M., Ciancanelli M., Alsina L., Azevedo J., Herman M., Anguiano E., Sancho-Shimizu V., Lorenzo L., Pauwels E., et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J Exp Med 2011, 208:2083-2098.
27. Sancho-Shimizu V., Perez de Diego R., Lorenzo L., Halwani R., Alangari A., Israelsson E., Fabrega S., Cardon A., Maluenda J., Tatematsu M., et al. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J Clin Invest 2011, 121:4889-4902.
28. Barreiro L.B., Ben-Ali M., Quach H., Laval G., Patin E., Pickrell J.K., Bouchier C., Tichit M., Neyrolles O., Gicquel B., et al. Evolutionary dynamics of human Toll-like receptors and their different contributions to host defense. PLoS Genet 2009, 5:e1000562.
29. Elinav E., Strowig T., Henao-Mejia J., Flavell R.A. Regulation of the antimicrobial response by NLR proteins. Immunity 2011, 34:665-679.
30. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
31. Tian X., Pascal G., Monget P. Evolution and functional divergence of NLRP genes in mammalian reproductive systems. BMC Evol Biol 2009, 9:202.
32. Kofoed E.M., Vance R.E. NAIPs: building an innate immune barrier against bacterial pathogens. NAIPs function as sensors that initiate innate immunity by detection of bacterial proteins in the host cell cytosol. Bioessays 2012, 34:589-598.
33. Atianand M.K., Fuchs T., Harton J.A. Recent evolution of the NF-kappaB and inflammasome regulating protein POP2 in primates. BMC Evol Biol 2011, 11:56.
34. Khare S., Dorfleutner A., Bryan N.B., Yun C., Radian A.D., de Almeida L., Rojanasakul Y., Stehlik C. An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages. Immunity 2012, 36:464-476.
35. Messaed C., Chebaro W., Di Roberto R.B., Rittore C., Cheung A., Arseneau J., Schneider A., Chen M.F., Bernishke K., Surti U., et al. NLRP7 in the spectrum of reproductive wastage: rare non-synonymous variants confer genetic susceptibility to recurrent reproductive wastage. J Med Genet 2011, 48:540-548.
36. Messaed C., Akoury E., Djuric U., Zeng J., Saleh M., Gilbert L., Seoud M., Qureshi S., Slim R. NLRP7, a nucleotide oligomerization domain-like receptor protein, is required for normal cytokine secretion and co-localizes with Golgi and the microtubule-organizing center. J Biol Chem 2011, 286:43313-43323.
37. Cummings J.R., Cooney R.M., Clarke G., Beckly J., Geremia A., Pathan S., Hancock L., Guo C., Cardon L.R., Jewell D.P. The genetics of NOD-like receptors in Crohn's disease. Tissue Antigens 2010, 76:48-56.
38. Kofoed E.M., Vance R.E. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 2011, 477:592-595.
39. Zhao Y., Yang J., Shi J., Gong Y.N., Lu Q., Xu H., Liu L., Shao F. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 2011, 477:596-600.
40. Faustin B., Lartigue L., Bruey J.M., Luciano F., Sergienko E., Bailly-Maitre B., Volkmann N., Hanein D., Rouiller I., Reed J.C. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell 2007, 25:713-724.
41. Masters S.L., Gerlic M., Metcalf D., Preston S., Pellegrini M., O'Donnell J.A., McArthur K., Baldwin T.M., Chevrier S., Nowell C.J., et al. NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity 2012, 37:1009-1023.
42. Atianand M.K., Duffy E.B., Shah A., Kar S., Malik M., Harton J.A. Francisella tularensis reveals a disparity between human and mouse NLRP3 inflammasome activation. J Biol Chem 2011, 286:39033-39042.
43. Fernandes-Alnemri T., Yu J.W., Juliana C., Solorzano L., Kang S., Wu J., Datta P., McCormick M., Huang L., McDermott E., et al. The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat Immunol 2010, 11:385-393.
44. Imamura R., Wang Y., Kinoshita T., Suzuki M., Noda T., Sagara J., Taniguchi S., Okamoto H., Suda T. Anti-inflammatory activity of PYNOD and its mechanism in humans and mice. J Immunol 2010, 184:5874-5884.
45. Eisenbarth S.C., Williams A., Colegio O.R., Meng H., Strowig T., Rongvaux A., Henao-Mejia J., Thaiss C.A., Joly S., Gonzalez D.G., et al. NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by dendritic cells. Nature 2012, 484:510-513.
46. Ha H.J., Kim D.S., Hahn Y. A 2.7-kb deletion in the human NLRP10 gene exon 2 occurred after the human-chimpanzee divergence. Biochem Genet 2009, 47:665-670.
47. Lech M., Avila-Ferrufino A., Skuginna V., Susanti H.E., Anders H.-J. Quantitative expression of RIG-like helicase, NOD-like receptor and inflammasome-related mRNAs in humans and mice. Int Immunol 2010, 22:717-728.
48. Schroder K., Sagulenko V., Zamoshnikova A., Richards A.A., Cridland J.A., Irvine K.M., Stacey K.J., Sweet M.J. Acute lipopolysaccharide priming boosts inflammasome activation independently of inflammasome sensor induction. Immunobiology 2012, 217:1325-1329.
49. Tanaka S., Saito Y., Kunisawa J., Kurashima Y., Wake T., Suzuki N., Shultz L.D., Kiyono H., Ishikawa F. Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD/SCID/IL2rgammaKO mice. J Immunol 2012, 188:6145-6155.
50. Rathinam C., Poueymirou W.T., Rojas J., Murphy A.J., Valenzuela D.M., Yancopoulos G.D., Rongvaux A., Eynon E.E., Manz M.G., Flavell R.A. Efficient differentiation and function of human macrophages in humanized CSF-1 mice. Blood 2011, 118:3119-3128.
51. Fairbairn L., Kapetanovic R., Sester D.P., Hume D.A. The mononuclear phagocyte system of the pig as a model for understanding human innate immunity and disease. J Leukoc Biol 2011, 89:855-871.
52. Fisher C.J., Agosti J.M., Opal S.M., Lowry S.F., Balk R.A., Sadoff J.C., Abraham E., Schein R.M.H., Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996, 334:1697-1702.
53. Rittirsch D., Hoesel L.M., Ward P.A. The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 2007, 81:137-143.
54. Arndt P., Abraham E. Immunological therapy of sepsis: experimental therapies. Intensive Care Med 2001, 27(Suppl 1):S104-S115.
55. Opal S.M., Fisher C.J., Dhainaut J.F., Vincent J.L., Brase R., Lowry S.F., Sadoff J.C., Slotman G.J., Levy H., Balk R.A., et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997, 25:1115-1124.
56. Fisher C.J., Dhainaut J.F., Opal S.M., Pribble J.P., Balk R.A., Slotman G.J., Iberti T.J., Rackow E.C., Shapiro M.J., Greenman R.L., et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994, 271:1836-1843.
57. Fortin C.F., McDonald P.P., Fulop T., Lesur O. Sepsis, leukocytes, and nitric oxide (NO): an intricate affair. Shock 2010, 33:344-352.